Suda Kenji, Kudo Yoshiyuki, Sugawara Yoko, Ishii Masahiro, Matsuishi Toyojiro
Department of Pediatrics and Child Health, Kurume University School of Medicine.
Nihon Rinsho. 2008 Feb;66(2):355-9.
Patients with coronary artery aneurysms caused by Kawasaki disease are at increased risk of coronary thrombosis and ischemia. To prevent coronary thrombosis, long-term anti-thrombosis using anti-platelet drugs, such as aspirin, dipyridamole, ticlopidine, clopidogrel, and abciximab, with or without warfarin is recommended by official guidelines. In fact, aspirin or aspirin with warfarin are the most frequently administered regimen in these patients with coronary aneurysms. However, there has been paucity of data and no randomized controlled study to determine the efficacy of these drugs. This short article attempts to summarize the efficacy and safety of these drugs based on currently available literatures and our multi-institutional experience.
川崎病所致冠状动脉瘤患者发生冠状动脉血栓形成和缺血的风险增加。为预防冠状动脉血栓形成，官方指南建议使用抗血小板药物（如阿司匹林、双嘧达莫、噻氯匹定、氯吡格雷和阿昔单抗）进行长期抗血栓治疗，可联合或不联合华法林。事实上，阿司匹林或阿司匹林联合华法林是这些冠状动脉瘤患者最常用的治疗方案。然而，目前缺乏数据，也没有随机对照研究来确定这些药物的疗效。这篇短文试图根据现有文献和我们多机构的经验总结这些药物的疗效和安全性。
